Literature DB >> 28787175

Targeted HAS2 Expression Lessens Airway Responsiveness in Chronic Murine Allergic Airway Disease.

Julia K L Walker1,2, Barbara S Theriot1, Michael Ghio1, Carol S Trempus3, Jordan E Wong1, Victoria L McQuade1, Jiurong Liang1, Dianhua Jiang1, Paul W Noble1, Stavros Garantziotis3, Monica Kraft1, Jennifer L Ingram1.   

Abstract

Hyaluronan (HA), a major component of the extracellular matrix, is secreted by airway structural cells. Airway fibroblasts in allergic asthma secrete elevated levels of HA in association with increased HA synthase 2 (HAS2) expression. Thus, we hypothesized that HA accumulation in the airway wall may contribute to airway remodeling and hyperresponsiveness in allergic airways disease. To examine this hypothesis, transgenic mice in which the α-smooth muscle actin (α-SMA) promoter drives HAS2 expression were generated. Mixed male and female α-SMA-HAS2 mice (HAS2+ mice, n = 16; HAS2- mice, n = 13) were sensitized via intraperitoneal injection and then chronically challenged with aerosolized ovalbumin (OVA) for 6 weeks. To test airway responsiveness, increasing doses of methacholine were delivered intravenously and airway resistance was measured using the forced oscillation technique. HA, cytokines, and cell types were analyzed in bronchoalveolar lavage fluid, serum, and whole lung homogenates. Lung sections were stained using antibodies specific for HA-binding protein (HABP) and α-SMA, as well as Masson's trichrome stain. Staining of lung tissue demonstrated significantly increased peribronchial HA, α-SMA, and collagen deposition in OVA-challenged α-SMA-HAS2+ mice compared with α-SMA-HAS2- mice. Unexpectedly, OVA-challenged α-SMA-HAS2+ mice displayed significantly reduced airway responsiveness to methacholine compared with similarly treated α-SMA-HAS2- mice. The total numbers of inflammatory cell types in the bronchoalveolar lavage fluid did not differ significantly between OVA-challenged α-SMA-HAS2+ mice and α-SMA-HAS2- mice. We conclude that allergen-challenged mice that overexpress HAS2 in myofibroblasts and smooth muscle cells develop increased airway fibrosis, which lessens airway hyperresponsiveness to bronchoconstrictors.

Entities:  

Keywords:  HAS2; airway hyperresponsiveness; asthma; hyaluronan

Mesh:

Substances:

Year:  2017        PMID: 28787175      PMCID: PMC5765419          DOI: 10.1165/rcmb.2017-0095OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  44 in total

1.  T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma.

Authors:  Wisam Al-Ramli; David Préfontaine; Fazila Chouiali; James G Martin; Ron Olivenstein; Catherine Lemière; Qutayba Hamid
Journal:  J Allergy Clin Immunol       Date:  2009-04-10       Impact factor: 10.793

Review 2.  Bronchial epithelium as a target for innovative treatments in asthma.

Authors:  Delphine Gras; Pascal Chanez; Isabelle Vachier; Aurélie Petit; Arnaud Bourdin
Journal:  Pharmacol Ther       Date:  2013-07-21       Impact factor: 12.310

Review 3.  Hyaluronan synthases.

Authors:  P H Weigel; V C Hascall; M Tammi
Journal:  J Biol Chem       Date:  1997-05-30       Impact factor: 5.157

Review 4.  Pathobiology of severe asthma.

Authors:  Humberto E Trejo Bittar; Samuel A Yousem; Sally E Wenzel
Journal:  Annu Rev Pathol       Date:  2014-11-24       Impact factor: 23.472

5.  Hyaluronan stimulates ex vivo B lymphocyte chemotaxis and cytokine production in a murine model of fungal allergic asthma.

Authors:  Sumit Ghosh; Scott A Hoselton; Steve B Wanjara; Jennifer Carlson; James B McCarthy; Glenn P Dorsam; Jane M Schuh
Journal:  Immunobiology       Date:  2015-02-07       Impact factor: 3.144

6.  Fluticasone inhibits the progression of allergen-induced structural airway changes.

Authors:  N J Vanacker; E Palmans; R A Pauwels; J C Kips
Journal:  Clin Exp Allergy       Date:  2002-06       Impact factor: 5.018

7.  Hyaluronan Controls the Deposition of Fibronectin and Collagen and Modulates TGF-β1 Induction of Lung Myofibroblasts.

Authors:  Stephen P Evanko; Susan Potter-Perigo; Loreen J Petty; Gail A Workman; Thomas N Wight
Journal:  Matrix Biol       Date:  2014-12-27       Impact factor: 11.583

8.  Overexpression of hyaluronan in the tunica media promotes the development of atherosclerosis.

Authors:  Song Chai; Qing Chai; Carl C Danielsen; Peter Hjorth; Jene R Nyengaard; Thomas Ledet; Yu Yamaguchi; Lars M Rasmussen; Lise Wogensen
Journal:  Circ Res       Date:  2005-02-10       Impact factor: 17.367

Review 9.  Airway remodeling: potential contributions of subepithelial fibrosis and airway smooth muscle hypertrophy/hyperplasia to airway narrowing in asthma.

Authors:  A M Bento; M B Hershenson
Journal:  Allergy Asthma Proc       Date:  1998 Nov-Dec       Impact factor: 2.587

10.  Pro- and anti-inflammatory factors cooperate to control hyaluronan synthesis in lung fibroblasts.

Authors:  Thomas S Wilkinson; Susan Potter-Perigo; Christina Tsoi; Leonard C Altman; Thomas N Wight
Journal:  Am J Respir Cell Mol Biol       Date:  2004-02-05       Impact factor: 6.914

View more
  4 in total

1.  Hyaluronan: Local Climate Change in Asthma?

Authors:  Philip L Sannes
Journal:  Am J Respir Cell Mol Biol       Date:  2017-12       Impact factor: 6.914

2.  Knockout of hyaluronan synthase 1, but not 3, impairs formation of the retrocalcaneal bursa.

Authors:  Katie J Sikes; Kristen Renner; Jun Li; K Jane Grande-Allen; Jennifer P Connell; Valbona Cali; Ronald J Midura; John D Sandy; Anna Plaas; Vincent M Wang
Journal:  J Orthop Res       Date:  2018-07-13       Impact factor: 3.494

Review 3.  Matrix remodeling in chronic lung diseases.

Authors:  Bon-Hee Gu; Matthew C Madison; David Corry; Farrah Kheradmand
Journal:  Matrix Biol       Date:  2018-03-17       Impact factor: 11.583

4.  Nitric oxide alters hyaluronan deposition by airway smooth muscle cells.

Authors:  Alana K Majors; Ritu Chakravarti; Lisa M Ruple; Rachel Leahy; Dennis J Stuehr; Mark Lauer; Serpil C Erzurum; Allison Janocha; Mark A Aronica
Journal:  PLoS One       Date:  2018-07-02       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.